Several studies have suggested that the addition of cystatin C measurements to creatinine measurements in calculating the eGFR significantly improves the risk classification for death, cardiovascular disease, and end-stage renal disease [41, 42]. Here, CST3 is linked to stage 5 chronic kidney disease.